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Abstract: Osteoporosis is a major health concern, which results in the increased risk of 
fractures. There is a high risk for the first or consecutive fractures leading to considerable 
morbidity and debilitating consequences if osteoporosis is untreated. Currently, bisphosphonates 
are the mainstay of treatment for osteoporosis though long-term persistence and adherence to 
bisphosphonates, especially those taken orally, remain low. This medication noncompliance 
has serious consequences on osteoporotic patients as it is associated with a significantly higher 
fracture risk. Intravenous (IV) zoledronic acid (ZOL), developed to increase compliance by 
overcoming the frequent and burdensome dosing requirements of oral bisphosphonates, is the 
first and the only once-yearly bisphosphonate globally approved for use in the treatment of up 
to 6 indications of osteoporosis. Several clinical studies have documented that a single infusion 
of IV ZOL resulted in decreased bone turnover and improved bone density for at least 12 
months post infusion. This article traces the development of ZOL ’s clinical utility and evaluates 
its patient preference by collating data from all major clinical trials, studying the efficacy and 
safety of ZOL in the treatment of osteoporosis and other benign bone disorders.
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Introduction
Osteoporosis
Osteoporosis, a chronic disease that affects an estimated 200 million people 
worldwide, is characterized by decreased bone mass, as well as weakened bones, 
with an increased risk of fractures. Often diagnosed late and subsequent to a fracture, 
it leads to significant morbidity and mortality.1,2 Osteoporosis can be classified into 
2 forms: primary and secondary. Primary osteoporosis results from cumulative 
bone loss as people age and go through changes in their sex hormones. Secondary 
osteoporosis results from a variety of medical conditions, diseases, or use of certain 
medications that adversely affect skeletal health.3 The World Health Organization 
(WHO) defines osteoporosis as a bone mineral density (BMD) with a T-score of $2.5 
standard deviations below the gender-specific young adult mean (ie, T-score # −2.5), 
as measured by dual energy X-ray absorptiometry (DXA).4 However, total fracture 
risk reflects both BMD-dependent and BMD-independent risk factors, and the new 
WHO absolute fracture risk algorithm takes into account BMD, age, smoking, alcohol 
intake, personal or parental history of fracture, body mass index, corticosteroid use, 
and rheumatoid arthritis to predict individual patients 10-year probability of sustaining 
osteoporotic fractures.5,6Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Bisphosphonates
Bisphosphonates, which inhibit osteoclastic activity, are 
the most commonly used medications for the treatment of 
osteoporosis.7,8 Several formulations of bisphosphonates are 
currently available. Alendronate (ALN), risedronate (RIS), 
and ibandronate are oral bisphosphonates that have been 
widely used for the treatment of postmenopausal osteoporosis 
(PMO). These bisphosphonates were originally approved 
as a once-daily formulation. However, low adherence to 
daily therapy coupled with recognition of the long skeletal 
retention of these bisphosphonates led to the evolution of less-
frequently-dosed but bioequivalent formulations.9,10 Current 
bisphosphonate regimens include once-weekly ALN or RIS, 
once- or twice-monthly ibandronate and RIS, quarterly intra-
venous (IV) ibandronate, and once-yearly IV ZOL.8
Zoledronic acid
Zoledronic acid (ZOL) (Aclasta®/Reclast®; Novartis Pharma 
AG, Basel, Switzerland), a third-generation bisphosphonate 
available as an IV formulation (5 mg given once-yearly, 
recommended with daily supplementation of 500–1,200 mg 
elemental calcium plus 400–800 U of vitamin D), is approved 
globally for up to 6 indications.
i.    Treatment of PMO in women to reduce the incidence 
of hip, vertebral, and nonvertebral fractures and to 
increase BMD
ii.    Prevention of clinical fractures after hip fracture in men 
and women
iii. Treatment of osteoporosis in men
iv.    Treatment and prevention of glucocorticoid-induced 
osteoporosis (GIO)
v.  Prevention of PMO (in the United States)
vi.  Treatment of Paget’s disease of bone
In May 2009, ZOL was approved by the US Food and 
Drug Administration for use, once every 2 years to prevent 
osteoporosis in postmenopausal women with osteopenia 
in the United States.11 ZOL (Zometa®; Novartis Pharma 
AG, Basel, Switzerland) is also approved for the treatment 
of hypercalcemia of malignancy (HCM) and advanced 
malignancies involving bone.12
This article traces the development of ZOL ’s clinical util-
ity by collating data from all major clinical trials, studying 
the efficacy and safety of ZOL in the treatment of primary 
and secondary osteoporosis and other benign bone disorders. 
This article also reviews the patient preferences for differ-
ent osteoporosis medications with a special focus on ZOL. 
The pharmacology and mechanism of action of ZOL are 
not reviewed in this article as both have been extensively 
reviewed previously.13–24
Studies evaluating the therapeutic 
utility of ZOL
Clinical studies
Treatment of PMO
The clinical utility of ZOL in the treatment of PMO was 
evaluated in 3 randomized and 2 open-label trials.
early studies of ZOL
The potential of IV ZOL in the treatment of PMO was 
initially assessed by Reid et al25 in a placebo-controlled, 
dose-ranging, 1-year study. This phase II study randomized 
351 postmenopausal women aged 45–80 years to receive 
placebo or one of the following 5 ZOL regimens: 0.25 mg, 
0.5 mg, or 1 mg at 3-month intervals; a single 4-mg dose; or 
2 doses of 2 mg administered 6 months apart. Mean lumbar 
spine and femoral neck BMD was, on average, 4.3%–5.1% 
(P , 0.001) and 3.1%–3.5% (P , 0.001), respectively, 
higher in all the ZOL treatment groups vs the placebo group 
at the end of the study period. Significant decreases in bone 
turn over markers (BTMs) were also observed at the end 
of the study (49%–52% decrease in serum type I collagen 
C telopeptide [CTx] with ZOL vs 8% decrease in CTx 
with placebo; P , 0.01). These results indicated that ZOL 
infusions given even at intervals of up to 1 year produce 
similar effects on bone turnover and bone density as those 
achieved with daily oral dosing with bisphosphonates of 
proven efficacy against fractures.
The above 1-year trial had 2 consecutive, open-label, 
2-year extension phases. The objective of these extension 
studies was to assess the long-term efficacy and safety 
of prolonged use of ZOL for a further 4 years. A total of 
119 women who completed the 1-year core study entered 
the next phase. Majority of the patients who entered the 
first extension study received 1 mg ZOL every 3 months 
(total annual dose, 4 mg), and others with 0.5 mg ZOL 
every 3 months (total annual dose, 2 mg). Patients who 
entered the second extension study received either calcium 
only or ZOL 4 mg. All patients entering the active treatment 
arm of the second extension had previously received ZOL 
4 mg per year during core and extension 1 studies. Patients 
received treatment for 2, 3, or 5 years. Study results showed 
that BMD increased in all 3 subgroups by the end of the 
5-year study period in lumbar spine (6.4%–9%), proximal 
femur (4.9%–5.5%), distal radius (2.2%–3%), and total body Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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(3.6%–5%), whereas BTMs decreased. However, there was 
an insufficient reduction in BTMs and moreover levels of 
alkaline phosphatase and CTx increased from month 24 
onwards in patients treated for up to 5 years.26
The long duration of the study allowed trends to be 
identified regarding the degree of reduction in bone modeling 
achieved by ZOL and suitability of 4 mg as a total annual 
dose. The results showed that ZOL 4 mg once-yearly 
increased BMD and was effective in reducing BTMs over 
5 years. However, detailed analysis of BTM changes sug-
gested that the 4-mg dose caused insufficient reduction in 
remodeling activity and may not suffice to maintain the sup-
pression of bone resorption.26 This upward trend in BTMs, 
leading to insufficient reduction of bone turnover to keep 
stable reduction in remodeling activity, was similar to a 
previous trial in which an IV bisphosphonate (ibandronate) 
was underdosed.27 Therefore, the authors concluded that the 
same mechanism could also play a role in this study and to 
achieve a more pronounced suppression of bone turnover, 
a higher IV dose of ZOL might be required.26
The health outcomes and reduced 
incidence with zoledronic acid once 
yearly-pivotal fracture trial
The Health Outcomes and Reduced Incidence with Zole-
dronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-
PFT) was a large, international, multicenter, randomized, 
double-blind, placebo-controlled trial of 3 years duration 
in which 7,765 patients with PMO were randomized to 
receive either a 15-minute IV infusion of ZOL (5 mg) or 
placebo.28 This study showed that ZOL significantly reduced 
morphometric vertebral, clinical vertebral, hip, and nonver-
tebral fractures by 70%, 77%, 41%, and 25%, respectively 
(Table 1). The 3-year risk reduction (70%) in the incidence 
of the vertebral fractures with ZOL exceeded the reduction 
previously observed for oral bisphosphonates and other 
therapeutic interventions.28–35 Assessment of bone structure 
and microarchitecture was also performed in a subgroup 
of patients. Overall, the findings from the study indicated 
preservation of trabecular bone structure in the ZOL group 
at 3 years.36
First head-to-head study  
of ZOL vs ALN
The first head-to-head study involving ZOL and ALN was 
conducted by McClung et al.37 This noninferiority 12-month 
trial included postmenopausal women (age, 45–79 years) 
treated with ALN for at least 1 year prior to randomization. 
A total of 225 patients were randomized (1:1) to receive 
either a single IV infusion of ZOL 5 mg plus oral placebo or 
a weekly 70 mg ALN plus a single IV infusion of placebo. 
The study showed that single-infusion ZOL maintained 
BMD for 12 months, following the switch from oral ALN in 
women with osteoporosis (Table 1). At the end of the study 
period, the ZOL group experienced a 0.12% (standard error 
[SE] = 0.273) increase from baseline in lumbar spine BMD 
compared with the ALN group that had a 0.828% (standard 
error [SE] = 0.288) increase from baseline (95% confidence 
interval [CI], −1.491 to 0.075). The authors concluded that 
patients can be switched from oral ALN to ZOL infusion with 
maintenance of therapeutic effect for at least 12 months.
Effect on bone resorption markers
Saag et al38 investigated the onset of action and effects on 
bone resorption markers of a single-infusion ZOL vs weekly 
oral ALN. The 24-week trial randomized (1:1) 128 postmeno-
pausal women aged 45–79 years to receive either a single IV 
infusion of ZOL 5 mg plus oral placebo or a weekly oral 70 
mg ALN plus a single IV infusion of placebo. The primary 
end point was the change in N-telopeptide of type I collagen 
(NTx) at week 1 from baseline. A significantly lower mean 
urine NTx value was seen in the ZOL group compared with 
the ALN group at week 1 (15.2 nmol BCE [bone collagen 
equivalents]/mmol creatinine and 35.5 nmol BCE/mmol 
creatinine, respectively; P , 0.0001). Overall, ZOL caused 
a greater and more rapid reduction in BTMs compared with 
weekly ALN (Table 1). Moreover, results from this study 
also showed that the majority of patients were more satisfied 
with the annual ZOL infusion (59.8%), were more willing 
to take it for a long period of time (68.0%), and felt that 
the annual infusion was more convenient than once-weekly 
therapy (66.4%).
Prevention of PMO
ZOL is also approved for the prevention of PMO. The recom-
mended regimen is a 5-mg IV infusion once every 2 years 
over no less than 15 minutes. Data from a 2-year, randomized, 
multicenter, double-blind clinical study (n = 581) showed 
that ZOL significantly increased BMD at lumbar spine and 
total hip compared with placebo at month 24 for osteopenic 
women in early and late menopause.39
In another 2-year study in a volunteer sample of 
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ZOL or placebo,40 ZOL decreased mean levels of each 
of 4 BTMs by at least 38% (range, 38%–45%) for the 
duration of the study (P , 0.0001). After 2 years, BMD 
was higher in the ZOL group than in the placebo group at 
an average of 5.7% (95% CI, 4.0–7.4) at the lumbar spine, 
3.9% (2.2–5.7) at the proximal femur, and 1.7% (0.8–2.5) at 
the total body (P , 0.0001 for each skeletal site). Moreover, 
between-group differences in BTM and BMD were similar 
at 12 and 24 months.40
Hip fractures
Hip fractures are associated with increased morbidity, 
functional decline, and death in older adults.41 Mortality is 
increased with reported rates of 15%–25% in the year follow-
ing hip fracture.41,42 The clinical efficacy of ZOL in patients 
with a recent, low-trauma hip fracture was investigated in a 
large, randomized, double-blind, placebo-controlled, mul-
ticenter 5-year study known as the HORIZON-Recurrent 
Fracture Trial (HORIZON-RFT) (n = 2127), which is the only 
trial ever conducted to study the risk of fracture incidence in 
patients who have already sustained a hip fracture, in which 
the median duration of follow-up was 1.9 years.43 Patients 
included in the HORIZON-RFT study were men or women 
aged $50 years, who had a low-trauma hip fracture surgically 
repaired within the previous 90 days.43 Patients were random-
ized (1:1) to receive IV infusions of ZOL 5 mg or placebo 
once-yearly. The primary measure of efficacy was new clinical 
fracture (excluding toe, finger, and facial bone fractures, and 
those occurring in abnormal bone) over the duration of the 
study. Secondary efficacy measures included new hip fracture, 
nonvertebral fracture, and vertebral fracture and the change in 
BMD in the nonfractured hip (measured annually with DXA); 
and prespecified safety end points, including death.
Data from the study showed that once-yearly ZOL 5 mg 
IV was effective in reducing the risk of fractures develop-
ing in patients who recently had a low-trauma hip fracture 
(Table 1).43 ZOL significantly (P = 0.001) reduced the risk 
of any new clinical fracture by 35% relative to placebo, with 
8.6% of ZOL and 13.9% of placebo recipients experiencing 
such fractures at 2 years. ZOL also reduced the risk of most 
secondary end point fractures. After 2 years of treatment, the 
risk of nonvertebral (7.6% ZOL vs 10.7% placebo recipients) 
and vertebral fractures (1.7% ZOL vs 3.8% placebo recipi-
ents) were also significantly reduced (P , 0.05) by 27% and 
46% with ZOL relative to placebo, although the treatment 
groups did not significantly differ in terms of hip fracture 
risk (2.0% ZOL vs 3.5% placebo recipients).43
BMD at both the total hip and the femoral neck improved 
significantly (P , 0.001) with ZOL relative to placebo after 
12, 24, and 36 months of treatment. Moreover, clinically 
relevant losses of BMD (based on prespecified measures of 
bone safety) were observed in 2.4% ZOL vs 11.9% placebo 
recipients.43
A significant reduction in all-cause mortality in patients 
treated with ZOL was also observed: 9.6% patients in the 
ZOL group and 13.3% patients in the placebo group died, 
a 28% reduction in deaths from any cause in the ZOL 
group (P = 0.01).43
Post hoc analysis of the HORIZON-RFT study to examine 
whether the timing of the first infusion had any relationship 
to fracture and mortality benefit showed that patients infused 
2–12 weeks after hip fracture, showed significant reduction 
in clinical vertebral fractures, nonvertebral fractures, and 
hip fractures, as well as all-cause mortality (first trial ever 
to show a significant reduction in mortality after using an 
antiosteoporosis medication).44
Male osteoporosis
Male osteoporosis is an important public health issue and 
remains largely undertreated in general practice. Moreover, 
even though men experience fewer osteoporotic fractures 
than women, they have higher mortality after fracture.45 Two 
analyses provide evidence for the efficacy of ZOL in the 
treatment of osteoporosis in men, and based on these studies, 
ZOL was approved in the European Union (EU).
Data analyzed from the male subpopulation of the 3-year 
HORIZON-RFT trial43 showed that ZOL was significantly 
more effective than placebo in increasing total hip BMD 
in men at 12, 24, and 36 months and in increasing femoral 
neck BMD at 24 and 36 months.46 Though the study was not 
powered to show a reduction in clinical fractures in men, the 
2-year cumulative clinical fracture event rates were 7.45% 
and 8.7% for ZOL and placebo, respectively (Kaplan–Meier 
estimates).46 Moreover, the study showed that men experi-
enced greater absolute mortality benefit than women (6.4% 
vs 2.8%), although they had a similar reduction in the risk 
of death.47
A 2-year study randomizing 302 hypogonadal men to 
annual ZOL 5 mg IV or weekly oral ALN 70 mg demon-
strated that the ZOL group had 6.1% increase in lumbar spine 
BMD compared with the ALN group that had 6.2% increase 
at 24 months. At month 12 relative to baseline ZOL and ALN 
reduced serum CTx by 52% and 57%, urine NTx by 54% and 
59%, serum N-terminal propeptide of type I collagen (P1NP) Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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by 51% and 56%, serum bone-specific alkaline phosphatase 
(BSAP) by 22% and 25%, respectively (Table1). The majority 
of subjects preferred once-yearly IV infusion of ZOL 5 mg 
over once-a-week oral 70 mg ALN.48
Pediatric osteoporosis
The use of bisphosphonates in children with osteogenesis 
imperfecta is well established. Most of the reports in children 
are almost exclusively on IV pamidronate,49 although 
successful treatment with the oral bisphosphonates, such as 
ALN,50,51 has also been reported.
In a recently published study in children with osteogenesis 
imperfecta, patients were switched to ZOL (0.04–0.05 mg/kg 
every 4 months) for a mean of 3.4 years after pamidronate 
therapy (1 mg/kg per dose every 2 months) for a mean 
of 3.75 years. Results from the study showed that ZOL 
appeared to be similarly effective as pamidronate in 
improving vertebral BMD and in reducing fracture rates 
implying that ZOL may be considered a potential alternative 
to pamidronate infusions in this patient group.52
Geriatric osteoporosis
Osteoporosis is for the most part a disease of the aged. 
Intravenous bisphosphonates are an option in the elderly 
who cannot tolerate or may have difficulty adhering to 
oral bisphosphonate therapy. Once-yearly infusion of 
ZOL may significantly improve adherence, especially in a 
geriatric population. Post hoc analysis of pooled data from 
HORIZON-PFT28 and HORIZON-RFT43 determining the 
efficacy of ZOL in osteoporotic postmenopausal women 
aged $75 years has shown that once-yearly ZOL treatment 
over 3 years significantly reduced the risk of any clini-
cal fracture, clinical vertebral and nonvertebral fractures 
(Table1). These findings provide evidence of the efficacy 
of once-yearly ZOL 5 mg IV in osteoporosis patients of 
advanced age.53
Glucocorticoid-induced 
osteoporosis
Persistent use of glucocorticoids is a major cause for second-
ary osteoporosis, leading to bone loss and increased fracture 
risk.54–58 This increased risk is apparent in some patients 
within 3 months of starting glucocorticoids.56 Prevention 
and treatment of GIO has been established with bisphospho-
nates.58 Recently once-yearly ZOL 5 mg has been approved 
for the prevention and treatment of osteoporosis caused by 
long-term use of glucocorticoids.
The approval for the GIO indication for men and women is 
based on the study showing that annual ZOL 5 mg IV is more 
effective in treating bone loss than daily oral RIS in patients 
with GIO. The study investigated both the prevention and the 
treatment of GIO in 833 men and women (288 prevention 
vs 545 treatment subgroups).59 Over 1 year, ZOL produced 
significantly greater increases in BMD of the lumbar spine, 
femoral neck, trochanter, and total hip than RIS. The increase 
in BMD with ZOL was evident at 6 months, and ZOL was 
better than RIS at 12 months (Table1).59
Thalassemia-induced osteoporosis
Osteoporosis is an important cause of morbidity in beta-
  thalassemia patients. In a study by Otrock et al,60 18 thalassemia 
patients with osteoporosis were given ZOL 4 mg IV every 
3 months over a period of 12 months. Patients on ZOL had a 
significant increase in their lumbar spine, femoral neck, tro-
chanter, and total hip BMD measurements over the 12-month 
period. Patients in the control group did not have any significant 
change in BMD measurements. There was a significant change 
in the levels of osteocalcin and bone alkaline phosphatase 
(BAP) and also a significant decrease in the number of painful 
sites (bone pain) experienced by the patients.60,61
In another study, 66 thalassemia patients with osteoporosis 
were randomized (1:1:1) to receive ZOL 4 mg IV , every 6 or 
3 months, or to receive placebo every 3 months, for a period 
of 1 year. BMD of the lumbar spine, femoral neck, and 
wrist was determined before and 12 months after treatment. 
Patients treated with ZOL 4 mg IV every 6 months had no 
change in BMD; however, there was an increase in BMD 
with ZOL 4 mg IV given every 3 months. Both regimens of 
ZOL reduced pain.62 BMD remained higher than baseline 
after 24 months of stopping ZOL treatment.63
Overall, the data from the above studies suggest that ZOL 
may be an effective option for the treatment of osteoporosis 
in thalassemia patients.60–63
Localized transient osteoporosis
Localized transient osteoporosis (LTO; bone marrow edema) 
is an increasingly diagnosed condition characterized by 
acute onset of disabling bone pain, which typically occurs 
at a single skeletal site. Although its etiology is unknown, 
LTO has been linked to pregnancy and prolonged periods 
of exercise but with absence of previous trauma or surgical 
history, as in algodystrophy. Current treatment options are 
limited in number and provide inadequate efficacy except 
recent positive experience with IV bisphosphonates.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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A study by Ringe et al64 in 8 patients with LTO showed 
that ZOL was highly effective in reducing pain, measured 
by visual analog scale (VAS 1–10). Pain scores decreased 
from 9.4 (at baseline) to 0.4. BMD was restored with an 
average increase in the lumbar spine of 4.1% after 6 months 
of treatment and in the affected and unaffected hip area by 
9.4% and 3.0%, respectively (difference 6.4%, P , 0.01), 
improving mobility and quality of life (QoL) in patients with 
LTO of the hip.
Paget’s disease
Paget’s disease of bone is characterized by a dramatic increase 
in bone turnover (both formation and resorption) at one or more 
skeletal sites.65 The bone pain, skeletal deformity, pathologic 
fractures, secondary arthritis, neurologic complications, and 
deafness that may accompany this disease contribute to its 
substantial morbidity. Bisphosphonate therapy is the most 
commonly used treatment for Paget’s disease.65
In 2005, Reid and colleagues65 published results of a piv-
otal study comparing ZOL with RIS in patients with Paget’s 
disease. The paper combined 2 identical, double-blinded, 
randomized controlled trials, comparing ZOL with RIS. In the 
6-month trial, patients received either a single IV infusion of 
ZOL 5 mg (177 patients) or a daily 30 mg RIS for 2 months 
(172 patients). The primary end point was normalization or a 
75% reduction of serum alkaline phosphatase (SAP) levels in 
6 months. A pain scale, gait, and QoL measures were assessed 
as well. At the completion of this study, a greater number of 
patients treated with ZOL (96%) achieved the primary end 
point compared to those treated with RIS (74%, P , 0.001). 
Further, ZOL provided patients with a significantly shorter 
median time to first therapeutic response (64 days ZOL vs 
89 days RIS, P , 0.001).
In patients with Paget’s disease of bone, normalization 
of SAP correlates with a longer duration of biochemical 
remission. SAP levels were normalized in more patients in 
the ZOL-treated group (88.6%) than in the RIS-treated group 
(57.9%), P , 0.001. Bone turnover markers, including serum 
NTx and serum β-CTx, measuring osteoblast function (bone 
formation) and urinary α-CTx measuring osteoclast function 
(bone resorption) were all suppressed into the normal range 
earlier and more consistently in patients treated with ZOL, 
P , 0.001 (Table 1).
At a median of 190 days following the formal trial, only 
0.9% of patients on ZOL showed evidence of recurrent dis-
ease activity by biochemical markers compared with 25.6% of 
patients on RIS, P , 0.001. Although the study was designed 
to demonstrate the noninferiority of ZOL compared to RIS 
in the treatment of Paget’s disease, the authors concluded 
that “ZOL appeared to be superior in terms of the degree of 
disease suppression, the rate of onset of effect and (on the 
basis of preliminary data) the persistence of these effects 
beyond the six-month trial period.” In addition, there was a 
trend toward improved QoL in patients treated with ZOL.
In a follow-up extension trial of the above study published 
by Hosking et al,66 152 patients who had been treated with 
ZOL and 115 patients who had been treated with RIS were 
followed for 18 months to determine the length of remission 
and durability of bone suppression. A sustained therapeutic 
response was noted in 98% of those treated with ZOL vs 
57% of those treated with RIS (Table 1).
ZOL in oncology
Skeletal complications contribute substantially to the burden 
of disease in patients with bone metastases from solid tumors 
and in patients with multiple myeloma. Bone metastases are 
the most common cause of cancer-related pain and often 
require palliative therapy. ZOL is widely used as palliative 
therapy in patients with bone metastases secondary to a wide 
range of solid tumors, including prostate cancer, lung cancer, 
and renal cell carcinoma.67
ZOL received approval for the treatment of bone metas-
tases secondary to all solid tumor types and bone lesions 
from multiple myeloma based on the results of 3 large, 
randomized, phase III clinical trials enrolling more than 
3,000 patients.
These trials demonstrated that ZOL (4 mg via 15-minute 
IV infusion, every 3–4 weeks) effectively reduced the 
incidence of skeletal complications associated with malignant 
bone disease for patients with breast cancer, multiple 
myeloma, prostate cancer, or solid tumors other than breast 
or prostate cancer.68–71 The primary efficacy end point in all 
3 trials was the proportion of patients who experienced at 
least 1 skeletal-related event (SRE), defined as a pathologic 
fracture, spinal cord compression, radiotherapy to bone, 
or surgery to bone. Change in antineoplastic therapy to 
palliate bone pain was also included as an SRE only in the 
trial evaluating patients with prostate cancer. HCM was 
included as an SRE in the analysis of secondary end points. 
The results of these 3 international trials demonstrate that 
ZOL has significant and durable clinical benefit in reduc-
ing skeletal complications for patients with malignant bone 
involvement from multiple myeloma and a variety of solid 
tumors, including breast, prostate, and lung cancers.68–71 
ZOL is also being studied for the prevention of aromatase 
inhibitor-associated bone loss in women receiving adjuvant Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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hormonal therapy for early-stage breast cancer and also for 
the prevention of bone loss during androgen-deprivation 
therapy.72,73
Safety and tolerability of ZOL  
in osteoporosis and Paget’s disease
Data from several clinical trials have demonstrated 
that IV ZOL is generally well tolerated in patients with 
osteoporosis28,37 and Paget’s disease.65,66 In the present 
section, clinically significant adverse events (AEs) associ-
ated with the use of ZOL in osteoporosis are discussed. 
Tolerability data of ZOL vs placebo, ALN, and RIS is also 
evaluated.
Clinically significant AEs associated 
with ZOL
Acute-phase reactions
The most common AEs observed with ZOL are acute-phase 
reactions, usually characterized by flu-like symptoms, 
headache, pyrexia, arthralgia, and myalgia. Most of these 
symptoms occur within the first 3 days after infusion and 
tend to resolve within several days after administration 
(Table 2).28,74
Hypocalcemia
The incidence of hypocalcemia (a serum calcium level 
,2.075 mmol/L) with ZOL has been reported in some 
studies, although in most cases it was asymptomatic and 
transient.28,38,43,65 However, in patients with low normal 
calcium at onset, it is recommend to start with the regular 
calcium/vitamin D supplementation before the infusion 
of ZOL.
Renal function
Evaluation of the renal safety of once-yearly ZOL 5 mg in 
several studies has shown that administration of ZOL was not 
associated with any long-term detrimental effects on renal 
function. Generally, the renal effects were short term, mild, 
and transient.28,43,59 A minimal infusion time of ZOL of 15 
minutes, however, is mandatory to avoid an impairment of 
renal function.
Cardiovascular: atrial fibrillation
Individual studies of ZOL have found an increased incidence 
of atrial fibrillation (AF); however, larger epidemiological 
studies have found no increased risk of AF in patients 
receiving bisphosphonate treatment.
The only study in the HORIZON clinical trial program 
where AF was significantly increased as serious AE (SAE) 
was the HORIZON-PFT study; AF, as SAE, was found to 
be more frequent in patients who received ZOL compared 
with placebo (1.3% ZOL vs 0.5% placebo; P , 0.001).28 
Of the 50 events that occurred in patients receiving ZOL, 
47 (94%) occurred .30 days after infusion, when ZOL was 
no longer detectable in systemic circulation. Furthermore, 
electrocardiograms performed on a subset of 559 patients 
before and 9–11 days after treatment found no differences 
between the treatment groups.
In the HORIZON-RFT study, which included an older 
patient population with more comorbidities compared with 
other osteoporosis trials, the incidence of serious AF was 
similar with ZOL and placebo (1.0% ZOL vs 1.2% placebo).43 
When ZOL was compared with RIS in patients with GIO, no 
serious AF was reported in either of the treatment arms.59
Osteonecrosis of the jaw
In patients receiving high cumulative doses of IV bispho-
sphonates to prevent SRE associated with bone metastases 
or HCM, cases of osteonecrosis of the jaw (ONJ) have been 
reported. As most of these patients were also receiving 
cytotoxic chemotherapy or corticosteroids, it is difficult to 
determine the true impact of bisphosphonate treatment on 
risk of ONJ. In patients receiving lower cumulative doses 
of bisphosphonates for treatment of osteoporosis, very rare 
cases of ONJ have been reported.
The safety data from the HORIZON-PFT study showed 
that of the 7,714 patients in the study, there were only 2 cases 
of possible ONJ: one in a patient receiving ZOL and other in a 
patient receiving placebo. Both patients experienced delayed 
healing associated with infection, and both conditions were 
resolved after antibiotic therapy or debridement. In several 
other studies with ZOL for the treatment of osteoporosis and 
Paget’s disease, no cases of ONJ were reported.43,59,66
Overall, the incidence of ONJ in osteoporotic patients 
receiving ZOL is very low, and this can be managed with no 
special treatment beyond routine dental care.75
Tolerability
ZOL vs placebo
Data from the HORIZON trials show that ZOL was generally 
well tolerated, and there was no significant difference between 
the ZOL and placebo groups in terms of number of patients 
who had SAEs, or discontinued follow-up due to an AE. In 
the HORIZON-PFT study, the number of patients with AEs 
was significantly higher in the ZOL group (95.5% ZOL vs Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 1 Summary of key efficacy data for ZOL in the treatment of osteoporosis and Paget’s disease
Study No. of patients,  
N
Study design Intervention Key efficacy results
Black et al28  
(HORiZON-PFT)
7,765 3-year, randomized, double-blind, placebo-
controlled clinical trial in postmenopausal  
osteoporosis patients
ZOL 5 mg;  
placebo
•   70% reduction in morphometric 
vertebral fractures over 3 years
•   41% reduction in hip fractures over 
3 years
•   25% reduction in nonvertebral 
fractures over 3 years
Lyles et al43  
(HORiZON-RFT)
2,127 Multicenter, randomized, double-blind,  
placebo-controlled, parallel-group 5-year  
trial in patients who had already sustained hip 
fracture; median follow-up was 1.9 years
ZOL 5 mg;  
placebo
•   28% reduction in mortality after hip 
fracture
•   35% risk reduction of all new clinical 
fractures
•   46% risk reduction of all new clinical 
vertebral fractures and 27% risk 
reduction in new nonvertebral 
fractures
•   ZOL improved BMD at total hip and 
femoral neck
•   ZOL demonstrated fracture 
prevention across all patients, even 
those at highest risk of fracture
McClung et al37 225 1-year, double-blind, double-dummy study in 
postmenopausal osteoporosis patients
ZOL 5 mg;  
ALN 70 mg
•   Lumbar spine BMD remained stable 
with both treatments at 12 months
•   78.7% of patients preferred a once- 
a-year infusion to weekly oral 
therapy at the end of study
Saag et al38 128 24-week, multicenter, randomized,  
double-blind, double-dummy, active- 
controlled trial in postmenopausal  
osteoporosis patients
ZOL 5 mg;  
ALN 70 mg
•   Significantly greater relative change 
in urine NTx values at week 1 with 
ZOL vs ALN
•   ZOL group had significantly lower 
mean urine NTx values throughout 
the 24-week study vs the ALN group
•   ZOL caused greater and more rapid 
reduction in BTMs compared with 
weekly ALN
Reid et al59  
(GiO trial)
833 1-year, multinational, multicenter,  
randomized, double-blind, double-dummy, 
stratified, active-controlled clinical trial in the 
prevention and in the treatment of GiO
ZOL 5 mg;  
RiS 30 mg
•   ZOL demonstrated superior BMD 
increase at 12 months compared 
with oral daily RiS in both 
subpopulations
•   ZOL significantly decreased levels 
of β-CTx and P1NP compared with 
oral daily RiS in both the prevention 
and the treatment subpopulations
•   84% of all patients preferred annual 
iv over daily oral pills
Reid et al65  
(Paget’s disease- 
core studies)
357 2 identical, 6-month, randomized,  
double-blind, active-controlled trials  
in patients with Paget’s disease
ZOL 5 mg;  
RiS 30 mg
•   96% of patients achieved therapeutic 
responsea with ZOL vs 74% with RiS 
at 6 months
•   88.6% of patients achieved normal 
alkaline phosphatase with ZOL vs 
57.9% with RiS
•   ZOL produced significantly greater 
reductions in alkaline phosphatase 
than RiS
Hosking et al66 
(Paget’s disease-
extension study)
267 eligible patients from both core studies 
reexamined 24 months after treatment
ZOL 5 mg;  
RiS 30 mg
•   98% of those given ZOL maintained 
therapeutic responsea vs 57% of 
those given RiS at 24 months
(Continued )Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 1 (Continued  )
Study No. of patients,  
N
Study design Intervention Key efficacy results
Boonen et al53 
(geriatric 
osteoporosis)
3,887 A post hoc subgroup analysis of pooled data 
from the HORiZON-PFT and  
HORiZON-RFT.
ZOL 5 mg; 
placebo
•   At 3 years, incidence of any clinical, 
vertebral and non-vertebral fracture 
was significantly lower in ZOL 
group compared with placebo group 
(10.8% vs 16.6%, 1.1% vs 3.7%, and 
9.9% vs 13.7%, respectively).
Orwoll et al48  
(male  
osteoporosis)
302 Multicenter, double-blind, active-controlled, 
parallel-group study for 24 months in 
hypogonadal men
ZOL 5 mg;  
ALN 70 mg
•   ZOL increased BMD at lumbar 
spine, total hip, femoral neck, and 
trochanter and was noninferior to 
ALN at 24 months.
•   At month 12, the median changes 
from the baseline of markers for 
bone resorption β-CTx, urine NTx 
and P1NP formation, serum BSAP 
were comparable between ZOL and 
ALN groups.
Note: aTherapeutic response defined as normalization of alkaline phosphate or $75% decrease in excess alkaline phosphatase.
Abbreviations: ZOL, zoledronic acid; HORiZON-PFT, The Health Outcomes and Reduced incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial; HORiZON-
RFT, HORiZON-Recurrent Fracture Trial; BMD: bone mineral density; ALN, alendronate; NTx, N-telopeptide of type i collagen; BTM, bone turnover markers; GiO, 
glucocorticoid-induced osteoporosis; β-CTx, beta-serum type i collagen C telopeptide; P1NP, serum N-terminal propeptide of type i collagen; RiS, risedronate; BSAP, 
bone-specific alkaline phosphatase.
93.9% placebo; P = 0.002), driven primarily by larger number 
of AEs associated with postdose symptoms.28 However, in 
the HORIZON-RFT study, the difference in the number of 
AEs between both groups was not significant (82.3% ZOL 
vs 80.6% placebo).43
The incidence of death was significantly lower in ZOL 
than that in placebo recipients in the HORIZON-RFT study 
(9.6% ZOL vs 13.3% placebo; P = 0.01), but not in the 
HORIZON-PFT study (3.4% ZOL vs 2.9% placebo).28,43
The tolerability profile of ZOL was generally similar to 
that of placebo with regard to most cardiovascular-related 
AEs, and no long-term renal toxicity was associated with 
ZOL in patients from either the HORIZON-PFT or the 
HORIZON-RFT study.28,43
ZOL vs ALN
The overall incidence of AEs in recipients of ZOL 5 mg IV 
(once-yearly) was generally similar to that seen in recipients 
of oral ALN 70 mg once-weekly in a comparative trial of 
1-year duration (86.7% vs 80.4%).37 No patient died during 
the course of the study. Treatment-emergent SAEs were 
reported in 10.6% of ZOL recipients compared with 9.8% 
of ALN recipients; no SAEs were considered to be study 
drug related. Only 3.5% ZOL recipients and 0.9% ALN 
recipients discontinued treatment because of AEs. Within the 
first 3 days of initial drug administration, treatment-emergent 
AEs occurred in 36.3% of ZOL recipients compared with 
21.4% of ALN recipients (Table 2). Three or more days after 
initial administration, the incidence of treatment-emergent 
AEs was broadly similar in ZOL and ALN recipients (77.9% 
vs 73.2% of patients).37
Safety results from a study by Saag et al38 showed that 
a comparable proportion of patients reported AEs in each 
treatment group (ZOL 5 mg, 91.3%; ALN 70 mg, 86.4%). 
Transient, flu-like symptoms were the most common AEs in 
the ZOL group and resulted in a higher frequency of AEs in the 
group during the first 3 days of treatment (Table 2). After 3 days, 
AE rates were similar in both groups (79.7% ZOL vs 78.0% 
ALN). There were no deaths during this study. SAEs occurred 
in 2 patients in the ZOL group (osteoarthritis, chest pain) and 3 
patients in the ALN group (1 patella fracture, 2 osteoarthritis). 
None were considered related to the treatment.
ZOL vs RiS
Safety data from a comparative trial of 1-year duration that 
tested the effectiveness of once-yearly IV ZOL 5 mg vs daily 
oralRIS 30 mg, for the prevention and treatment of GIO, 
showed that the overall incidence of SAEs was similar between 
the ZOL and RIS groups, but AEs were more common with 
ZOL than with RIS largely as a result of transient, flu-like 
symptoms during the first 3 days after infusion (Table 2).59
In the treatment subgroup, the most frequently reported 
SAE for patients tested with ZOL and RIS was worsening 
rheumatoid arthritis, which was judged to be severe in 2% 
of patients in each drug group.
In the prevention subgroup, the most frequently 
reported SAE was pyrexia, which was judged to be severe 
in 1% of patients in each drug group. No signifcant Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 2 Summary of five most frequently reported AEs after first infusion of ZOL in the treatment of osteoporosis and Paget’s disease 
compared with placebo, ALN and RiS
Study Intervention N Any AE, 
n (%)
Five typical AEs within 3 days of initial dosinga
Pyrexia,  
n (%)
Myalgia,  
n (%)
Influenza-like 
symptoms,  
n (%)
Headache, 
n (%)
Arthralgia,  
n (%)
ZOL vs placebo
Reid et al25 ZOL
4 × 0.25 mg 60 52 (87) 6 (10) 12 (20) 1 (2) Not reported 9 (15)
4 × 0.5 mg 58 50 (86) 5 (9) 6 (10) 4 (7) 8 (14)
4 × 1 mg 53 50 (94) 7 (13) 7 (13) 2 (4) 9 (17)
2 × 2 mg 61 56 (92) 12 (20) 10 (16) 10 (16) 15 (25)
1 × 4 mg 60 54 (90) 9 (15) 6 (10) 9 (15) 5 (8)
Placebo 59 45 (76) 2 (3) 1 (2) 4 (7) Not reported 9 (15)
Black et al28 
(HORiZON-PFT)
ZOL 5 mg
Placebo
3862
3852
3688 (95.5)
3616 (93.9)
621 (16.1)
79 (2.1)
365 (9.5)
66 (1.7)
301 (7.8)
61 (1.6)
273 (7.1)
90 (2.3)
245 (6.3)
76 (2.0)
Lyles et al43 
(HORiZON-RFT)
ZOL 5 mg
Placebo
1054
1057
867 (82.3)
852 (80.6)
73 (6.9)
9 (0.9)
33 (3.1)
9 (0.9)
6 (0.6)
3 (0.3)
16 (1.5)
9 (0.9)
33 (3.1)
23 (2.2)
ZOL vs ALN
McClung et al37 ZOL 5 mg  113 98 (86.7) Not reported Not reported Not reported 14 (12.4) 6 (5.3)
ALN 70 mg 112 90 (80.4) Not reported Not reported Not reported 7 (6.3) 1 (0.9)
Saag et al38 ZOL 69 63 (91.3) 4(5.8) 8 (11.6) 13 (18.8) 5 (7.2) 5 (7.2)
ALN 70 mg 59 51 (86.4) 1 (1.7) 1 (1.7) 3 (5.1) 7 (11.9) 4 (6.8)
ZOL vs RIS
Reid et al65 ZOL 5 mg 177 146 (82.5) 13 (7.3) 13 (7.3) 17 (9.6) 12 (6.8) Not reported
RiS 30 mg 172 133 (77.3) 1 (0.6) 6 (3.5) 7 (4.1) 7 (4.1) Not reported
Reid et al59 
(Treatment group)
ZOL 5 mg
RiS 30 mg
272
273
211 (78)
186 (68)
32 (12)
12 (4)
29 (11)
6 (2)
15 (6)
3 (1)
13 (5)
5 (2)
32 (12)
21 (8)
Reid et al59 
(Prevention group)
ZOL 5 mg
RiS 30 mg
144
144
111 (77)
93 (65)
21 (15)
3 (2)
9 (6)
8 (6)
10 (7)
1(1)
9 (6)
5 (3)
9 (6)
10 (7)
Note: aThe 5 symptoms listed were the most frequently cited in Black et al28 and other studies.
Abbreviations: Ae, adverse event; ZOL, zoledronic acid; ALN, alendronate; RiS, risedronate; N, number of patients; HORiZON-PFT, The Health Outcomes and Reduced 
incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial; HORiZON-RFT, HORiZON-Recurrent Fracture Trial.
differences were recorded between the drug groups in 
either the treatment or the prevention subgroups within 
the cardiac disorders.59 In the treatment subgroup, the 
incidence of death was comparable between ZOL and 
RIS, (1% ZOL vs 1% RIS). However, in the prevention 
subgroup, it was slightly higher in the ZOL vs RIS groups 
(1% ZOL vs 0% RIS).
In a study by Reid et al65 comparing ZOL with RIS in 
patients with Paget’s disease, the number of patients with 
AEs (146 ZOL vs 133 RIS; Table 2) and SAEs (9 ZOL vs 
11 RIS) were similar in the 2 groups. In the first 3 days, the 
ZOL group had twice the number of AEs as compared to the 
RIS group (P , 0.001), and these were principally the flu-like 
symptoms, known to occur in association with the IV use of 
nitrogen-containing bisphosphonates (Table 2). Subsequently, 
the rates of AEs were similar in the 2 groups. The frequen-
cies of gastrointestinal and renal or urinary disorders were 
similar in the 2 groups. An 18-month extension of the study 
showed that death rates and SAEs were similar between 
ZOL and RIS.66
Patient considerations  
and treatment preference
Several large clinical trials have shown the efficacy of 
bisphosphonates in the treatment of osteoporosis. However, 
the long-term treatment with bisphosphonates is required 
for optimal and sustained benefit. Therefore, compliance 
and adherence to prescribed medication are needed for an 
evaluable therapeutic benefit to patients.76
In the treatment of osteoporosis, nonadherence to bis-
phosphonate therapy correlates with reduced gains in BMD 
and lower reductions in the levels of BTMs.77,78 In addition, 
nonadherence leads to an increased incidence of secondary 
complications associated with fractures, such as pain, Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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nosocomial infections, and pulmonary thromboembolism, 
and hence to a decreased QoL.78–81
Reasons for the suboptimal 
adherence to earlier developed 
bisphosphonates
The main reasons patients cite for not continuing to take 
their osteoporosis medication are the stringent dosing 
schedule, AEs, not feeling that treatment is working, and not 
believing that they have a disease that needs to be treated.76 
The commonest reasons were the strict dosing requirements 
for oral bisphosphonates (fasting overnight or for at least 6 
hours prior to taking the medication and 30–60 min after 
administration) and posture (staying upright for 30–60 
minutes after taking the medication), which can be inconve-
nient and often not feasible in the daily routine. The second 
most common reason for discontinuation of therapy is side 
effects. The main complaints with oral bisphosphonates are 
upper gastrointestinal irritation, dyspepsia, nausea, upper 
abdominal pain, vomiting, and gastroesophageal reflux. 
Finally, as patients often have no symptoms until they suffer 
a fracture, they do not feel that treatment is worth taking 
or do not believe they have a disease that needs treatment. 
They may consider the pill a burden and the inconvenience 
of the dosing requirements to be unnecessary.76
Evolution of dosing regimens  
to overcome nonadherence
Initially, all the studies for oral bisphosphonates (ALN, 
RIS, and ibandronate), which showed antifracture efficacy, 
were conducted using a daily regimen.29–31,33,82 However, 
the burdensome dosing requirements needed for gastro-
intestinal protection with daily oral bisphosphonates led 
to the development of less-frequent oral regimens. As the 
half-life of bone-bound bisphosphonates is long, weekly 
dosing of bisphosphonates is possible; moreover, they 
remain at resorption sites longer than the 2-week lifespan 
of individual osteoclasts.83 Weekly oral ALN and RIS 
achieved approval based on comparisons with the respec-
tive daily regimens.84,85 Weekly oral ibandronate has also 
shown noninferior efficacy to the daily regimen86 but has not 
been marketed. Bisphosphonate pharmacology also makes 
possible monthly, intermittent, quarterly, or yearly dosing. 
To improve adherence and persistence, these extended inter-
val regimens were developed. Monthly oral ibandronate, 
the first approved monthly bisphosphonate regimen, was 
  supported by comparison trials with the daily regimen and 
is in use since 2005.34,87 An intermittent oral RIS regimen 
(2 consecutive days monthly) was approved in April 2007,88 
and a once-monthly RIS dosing regimen was approved in 
April 2008.89
Intravenous bisphosphonate regimens do not require 
stringent dosing requirements as oral bisphosphonates, and 
therefore, it provides alternative options for osteoporosis 
patients unable to take oral bisphosphonates. Quarterly IV 
ibandronate injection (3 mg/3 months) became, in 2006, 
the first IV bisphosphonate to be approved for PMO in the 
United States and in the EU. Quarterly IV ibandronate has 
shown efficacy in PMO with a similar safety profile to the 
monthly oral regimen.90 This was followed by once-yearly 
ZOL 5 mg IV , which is approved globally for up to 6 indica-
tions in osteoporosis. It provides the greatest extended dos-
ing interval and reduces concerns about oral administration, 
gastrointestinal intolerance, and bioavailability. The efficacy 
and safety of ZOL have been demonstrated from several large 
randomized trials.28,37,38,43
Patient preference for once-yearly 
ZOL dosing
A once-yearly IV ZOL has been preferred by a majority 
of trial outpatients in 2 separate trials, who switched to 
ZOL from weekly oral ALN.37,38 McClung et al37 reported 
that 79% of patients preferred an annual infusion of ZOL 
vs weekly oral ALN. Similarly, Saag et al38 reported that 
a majority of patients (66%) preferred for annual ZOL vs 
weekly ALN. Moreover, patients who cannot tolerate or 
do not prefer oral dosing may opt for yearly IV infusion 
of ZOL.28 Intravenous regimens may also be particularly 
advantageous for elderly patients residing in long-term 
care facilities or those with impairments affecting self-
management of medication.91
Optimizing the dosing interval  
for ZOL
Optimizing the dosing interval for ZOL is important. It is 
likely that even less frequent administration of ZOL will 
become more acceptable to patients and hence associated 
with greater adherence to long-term therapy. It has been 
demonstrated that the duration of antiresorptive action of a 
single 5-mg dose of ZOL exceeds 12 months, and it would 
be worth evaluating the antifracture efficacy of ZOL with a 
dosing interval of more than 12 months.92Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
242
Ringe
Place of ZOL in the treatment  
of osteoporosis
In randomized clinical trials, ZOL 5 mg has been proven to 
be effective in reducing the risk of vertebral, nonvertebral 
and hip fractures, and to be generally well tolerated in 
PMO.28 ZOL is the only bisphosphonate to have demon-
strated significant risk reduction at all major osteoporotic 
fracture sites. The 70% relative risk reduction in vertebral 
fracture at 3 years demonstrated by once-yearly ZOL 
5 mg28 is numerically greater than the relative risk reduc-
tions shown by ALN (44%)82 or RIS (49%).93 ZOL 5 mg 
has also been shown to be effective in the prevention of 
clinical fracture in patients (male and female) who have 
previously experienced a low-trauma hip fracture.43 ZOL 
5 mg is the only agent with demonstrated efficacy in this 
indication. ZOL is also significantly more effective than 
RIS in preventing and treating GIO.59 Most recently, the 
efficacy of ZOL in treating osteoporosis in men has also 
been demonstrated.47,48 The formulation and administration 
regimen of ZOL 5 mg ensures year-long effectiveness. Thus, 
it presents an attractive alternative to other daily, weekly, 
or monthly bisphosphonate therapies. Moreover, several 
studies are underway to determine the efficacy of ZOL 
compared with other bisphosphonates, ie, ZOL is being 
compared with pamidronate in heart- and lung-transplant-
related osteopenia and osteoporosis, with ALN in heart and 
liver transplantations and with ALN in kidney and kidney/
pancreas transplantations.94
Conclusions
The main aim of treatment in osteoporosis is to reduce the risk 
of fractures, thereby reducing fracture-associated morbidity 
and mortality. A once-yearly administration of ZOL 5 mg has 
the potential to help meet this main clinical need of patients 
with osteoporosis because clinical evidence suggests that it 
is more effective than oral bisphosphonates in reducing the 
risk of vertebral and hip fractures, and it improves compliance 
through provision of medication over the entire 1-year period 
in a formulation that is well tolerated.
Review criteria
Searches were performed using PubMed to find material 
published in English between 2000 and 2009. We used the 
search terms zoledronic acid, bisphosphonates, osteoporosis, 
secondary osteoporosis, clinical utility, adherence, patient 
preference, and Paget’s disease to find full-text articles and 
abstracts. Reference lists from various articles were also 
searched for further sources.
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